Belite Bio (NASDAQ:BLTE) Announces Earnings Results

Belite Bio (NASDAQ:BLTE) posted its quarterly earnings results on Wednesday. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.29, FiscalAI reports.

Here are the key takeaways from Belite Bio’s conference call:

• Belite Bio said it received the phase III clinical study report for Tinlarebant in Stargardt disease and began its NDA rolling submission to the FDA in April, with completion targeted for Q2 2026.
• Management said FDA discussions supported a potential single-study approval path based on the robustness of the DRAGON 1 data, while DRAGON II is primarily intended to satisfy Japan regulatory requirements.
• The company has begun building its commercial organization, with all commercial leadership hired and a planned launch team of about 30 to 40 people focused on disease awareness, genetic testing, and drug promotion.
• Belite Bio remains focused on the Stargardt opportunity first, while its geographic atrophy program is still in development with an interim readout targeted for around end of year and strategy to be determined by the data.
• The company ended Q1 with a strong $799 million cash position after ESOP and warrant proceeds, which management said should fund NDA completion, commercialization prep, and ongoing trials.

Belite Bio Trading Up 2.6%

BLTE stock opened at $143.36 on Thursday. The firm has a 50 day moving average of $160.58 and a 200-day moving average of $156.47. Belite Bio has a 12-month low of $56.10 and a 12-month high of $200.00. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -62.33 and a beta of -1.19.

Insider Activity

In other news, insider Nathan L. Mata sold 666 shares of Belite Bio stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $153.21, for a total transaction of $102,037.86. Following the completion of the sale, the insider directly owned 440 shares in the company, valued at approximately $67,412.40. This trade represents a 60.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 26,166 shares of company stock worth $4,548,351. 13.29% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Belite Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its position in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after acquiring an additional 282 shares during the period. Bank of America Corp DE raised its position in shares of Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Belite Bio during the 4th quarter worth approximately $108,000. EverSource Wealth Advisors LLC acquired a new position in shares of Belite Bio during the 2nd quarter worth approximately $147,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Belite Bio during the 2nd quarter worth approximately $190,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Mizuho set a $223.00 target price on Belite Bio in a research report on Thursday, February 19th. Wall Street Zen upgraded Belite Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Bank of America assumed coverage on Belite Bio in a research report on Monday, January 26th. They set a “buy” rating and a $195.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a research report on Tuesday, April 7th. Finally, Morgan Stanley lifted their target price on Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $202.33.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.